Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma
Acta Pharmaceutica Sinica B
; (6): 488-504, 2021.
Article
in En
| WPRIM
| ID: wpr-881149
Responsible library:
WPRO
ABSTRACT
Medulloblastoma (MB) is a common yet highly heterogeneous childhood malignant brain tumor, however, clinically effective molecular targeted therapy is lacking. Modulation of hedgehog (HH) signaling by epigenetically targeting the transcriptional factors GLI through bromodomain-containing protein 4 (BRD4) has recently spurred new interest as potential treatment of HH-driven MB. Through screening of current clinical BRD4 inhibitors for their inhibitory potency against glioma-associated oncogene homolog (GLI) protein, the BRD4 inhibitor
Full text:
1
Database:
WPRIM
Language:
En
Journal:
Acta Pharmaceutica Sinica B
Year:
2021
Document type:
Article